Yes to all three questions. My point is that a few individuals respond
better than predicted by aggregated trial data. It would be unfair to deny
the drug to the responsive minority because of the majority experience.
Better to restrict usage to those individuals whose objectively measured
improvement after a reasonable trial exceed a preset threshold.
> -----Original Message-----
> From: [log in to unmask]
> [mailto:[log in to unmask]]On Behalf Of
> [log in to unmask]
> Sent: 29 September 1998 22:32
> To: [log in to unmask]
> Subject: RE: orlistat
>
>
> > From: "Mark Pasola" <[log in to unmask]>
>
> <snip>
> > Agreed in general but the benefits of Aricept are not always minimal. A
> > patient of mine has improved his mini-mental state score from
> 20 to 26, and
> > he can certainly tell the difference.
> >
> Yes, but has his 'daily activities' improved?
> Has his 'independence' improved?
> Have his relatives/carers noticed any difference and an improvement
> in *their* lot?
>
> Dr David J Plews
> ------------------------
>
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|